Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on April 1, 2025
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to …
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
GlobeNewswire
·
April 1, 2025
124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare …
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire
·
April 1, 2025
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation …
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
GlobeNewswire
·
April 1, 2025
CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a …
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
GlobeNewswire
·
April 1, 2025
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl …
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
GlobeNewswire
·
April 1, 2025
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on …
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
GlobeNewswire
·
April 1, 2025
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in …
Medicenna to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Codexis Appoints Cynthia Collins to Board of Directors
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s …
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
GlobeNewswire
·
April 1, 2025
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N.J., April 01, 2025 (GLOBE …
Sysmex’s PA-100 AST System: Revolutionising UTI diagnosis and treatment with precision
GlobeNewswire
·
April 1, 2025
PARIS, April 01, 2025 (GLOBE NEWSWIRE) -- Sysmex’s PA-100 AST System is redefining standard of care for diagnosing and treating urinary tract infections (UTIs). By combining cutting-edge nanofluidic technology with rapid antimicrobial susceptibility …
Le Système PA-100 AST de Sysmex : Révolutionner le diagnostic et le traitement des IU avec précision
GlobeNewswire
·
April 1, 2025
PARIS, 01 avr. 2025 (GLOBE NEWSWIRE) -- Le Système PA-100 AST de Sysmex redéfinit les normes de soins pour le diagnostic et le traitement des infections urinaires (IU). En associant une technologie nanofluidique de pointe à un antibiogramme rapide, le …
Teleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP)
GlobeNewswire
·
April 1, 2025
WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology …
ITM Appoints Dr. Celine Wilke as Chief Medical Officer
GlobeNewswire
·
April 1, 2025
Experienced leader in radiopharmaceutical drug development, regulatory, and clinical strategies will advance ITM’s broad pipeline and clinical development strategy Garching / Munich, Germany, April 01, 2025 – ITM Isotope Technologies Munich SE (ITM), a …
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
GlobeNewswire
·
April 1, 2025
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant …
Best Testosterone Supplement For Men Over 40 and 50: Testo Prime for For Muscle Gain & Erectile Dysfunction 2025 By (Testo Prime)
GlobeNewswire
·
April 1, 2025
GLASGOW, United Kingdom, April 01, 2025 (GLOBE NEWSWIRE) -- If you’re a man over 50, you have likely seen first-hand how your body changes as you get older. Working out feels like a chore, you seem to notice new aches and pains every day, and your libido …
Nxera Pharma Announces Appointments to its Executive Leadership Team
GlobeNewswire
·
April 1, 2025
Mr. Kiyoshi Kaneko appointed as Chief Commercial Officer, and Ms. Mariko Nakafuji promoted to Chief Legal Officer Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new …
ProDentim Reviews (Complaints & Side Effects) – 2025 Update: Real Users Reveal the Truth About Benefits and Results
GlobeNewswire
·
April 1, 2025
TALLMADGE, Ohio, April 01, 2025 (GLOBE NEWSWIRE) -- ProDentim is quickly becoming one of the most talked-about dental supplements in America, revolutionizing the way people approach oral healthcare. With over 30,000 users sharing their experiences, the …
Buy Clenbuterol: Best Legal Clenbuterol Steroids For Weight Loss & Clen Cutting Cycle For Sale From CrazyBulk
GlobeNewswire
·
April 1, 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Clenbuterol is used by both men and women to lose weight, raises metabolic rate and aids in fat reduction. Taking clenbuterol may also help users keep lean muscle and strength. This product is popular among …
Anavar For Women: Dosage, Pills (Before & After Cycle Results) – Buy Legal Anavar Steroid For Female From CrazyBulk
GlobeNewswire
·
April 1, 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- If you are a female individual contemplating the usage of steroids to support your weight management and health and fitness objectives, Anavar may have emerged as a viable option. >> Shop Anvarol on the Official …